United States · Funded startup
Funding summaryUpdated 26 Oct 2026
$166Mraised across 4 rounds since 2015, from 4 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Source recorded
Redmile Group
SpheraReported by EndptsSEC filing: $26M sold, first sale Jan 2017
Cormorant Asset ManagementRedmile Group
Jennison Associates
Sanofi-Genzyme BioVentures
Fidelity Management and Research Company
Tekla Capital ManagementFrom a historical funding recordSEC filing: $75M sold, first sale Aug 2015
No investor was named in the report.
From a historical funding recordSEC filing: $5.1M sold, first sale Oct 2014
From Ovid Therapeutics's own website and the SEC filings it signed: 7 on the team.
On the board, as filediBart M. FriedmanDouglas E. WilliamsKaren E. Bernstein
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Redmile GroupCormorant Asset Management
RA Capital Management
Janus Henderson InvestorsJennison AssociatesSanofi-Genzyme BioVenturesFidelity Management and Research CompanyTekla Capital ManagementSpheraDoubleLine Equity Healthcare FundMissing a round, or an investor who was in one? Tell us.
Ovid Therapeutics's investors include Redmile Group, Cormorant Asset Management, RA Capital Management, Janus Henderson Investors and Jennison Associates, and 10 more on record.
Ovid Therapeutics has raised $166M across 4 rounds since 2015.
Ovid Therapeutics's most recent round was an Undisclosed round of $60M in Mar 2026.
Ovid Therapeutics's largest round on record is $75M (Series B), in Aug 2015.
Ovid Therapeutics's first round on record, in Aug 2015, was backed by Cormorant Asset Management, Redmile Group and Jennison Associates and 5 others.
Ovid Therapeutics's latest named round is an Undisclosed round, in Mar 2026.
Ovid Therapeutics is based in the United States.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States · 
